| Literature DB >> 29910175 |
Gerónimo Fernández1, Ana Moraga2, María I Cuartero2, Alicia García-Culebras2, Carolina Peña-Martínez2, Jesús M Pradillo2, Macarena Hernández-Jiménez3, Silvia Sacristán4, M Irene Ayuso5, Rafael Gonzalo-Gobernado5, David Fernández-López2, M Elena Martín4, María A Moro2, Victor M González6, Ignacio Lizasoain7.
Abstract
Since Toll-like receptor 4 (TLR4) mediates brain damage after stroke, development of TLR4 antagonists is a promising therapeutic strategy for this disease. Our aim was to generate TLR4-blocking DNA aptamers to be used for stroke treatment. From a random oligonucleotide pool, we identified two aptamers (ApTLR#1R, ApTLR#4F) with high affinity for human TLR4 by systematic evolution of ligands by exponential enrichment (SELEX). Optimized truncated forms (ApTLR#1RT, ApTLR#4FT) were obtained. Our data demonstrate specific binding of both aptamers to human TLR4 as well as a TLR4 antagonistic effect. ApTLR#4F and ApTLR#4FT showed a long-lasting protective effect against brain injury induced by middle cerebral artery occlusion (MCAO), an effect that was absent in TLR4-deficient mice. Similar effects were obtained in other MCAO models, including in rat. Additionally, efficacy of ApTLR#4FT in a model of brain ischemia-reperfusion in rat supports the use of this aptamer in patients undergoing artery recanalization induced by pharmacological or mechanical interventions. The absence of major toxicology aspects and the good safety profile of the aptamers further encourage their future clinical positioning for stroke therapy and possibly other diseases in which TLR4 plays a deleterious role.Entities:
Keywords: SELEX; TLR4; aptamer; infarction; inflammation; ischemia; stroke; therapy
Mesh:
Substances:
Year: 2018 PMID: 29910175 PMCID: PMC6094477 DOI: 10.1016/j.ymthe.2018.05.019
Source DB: PubMed Journal: Mol Ther ISSN: 1525-0016 Impact factor: 11.454